Fig. 2From: Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)Trends of in vitro susceptibility to ceftazidime–avibactam against various bacterial species over time in different regions using the CLSI breakpoint. AM Africa/Middle-East, EU Europe, LA Latin America, NA North America, OC Oceania. Data are not presented for Oceania due to limited number of isolatesBack to article page